Crossmark

Assessing synovitis in the hands in patients with rheumatoid arthritis by ultrasound: an agreement study exploring the most inflammatory active side from two Norwegian trials

Crossref DOI link: https://doi.org/10.1186/s13075-019-1930-y

Published Online: 2019-07-05

Published Print: 2019-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Terslev, Lene https://orcid.org/0000-0001-8193-9471
Christensen, Robin

Aga, Anna-Birgitte

Sexton, Joe

Haavardsholm, Espen A.

Hammer, Hilde B.
License Information

Text and Data Mining valid from 2019-07-05

Version of Record valid from 2019-07-05
More Information

Article History

Received: 7 April 2019

Accepted: 4 June 2019

First Online: 5 July 2019

Ethics approval and consent to participate

: The ULRABIT and ARCTIC studies were approved by the Regional Committee for Medical and Health Research Ethics South East, Norway, and all patients gave written consent according to the Declaration of Helsinki.

: Not applicable.

: Lene Terslev: speaker's fee from Roche, MSD, BMS, Pfizer, AbbVie, Novartis, and Janssen.Anna-Birgitte Aga: Advisory boards for UCB, AbbVie and Pfizer, honoraria for development of educational material for UCB.Espen Haarvardsholm: Research funding from Pfizer, UCB, Roche, MSD and AbbVie, honoraria as a speaker from Pfizer, UCB, Roche, and AbbVie, honoraria for development of educational material from Pfizer, and has been on advisory board for Pfizer.Hilde Berner Hammer: Study grants from AbbVie/Pfizer and Roche. Speaker fees from AbbVie, Bristol-Myers Squibb, Roche, UCB Pharma, and Pfizer.The other authors declare that they have no competing interests.

Document is current

Any future updates will be listed below